<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Isosorbide Mononitrate</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01020</strong>&#160; (APRD00528)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Isosorbide mononitrate is a drug used principally in the treatment of angina pectoris<sup class="footnote" id="fnr1"><a href="#fn1">1</a></sup> and acts by dilating the blood vessels so as to reduce the blood pressure. It is sold by AstraZeneca under the trade name Imdur.</p>
<p>Isosorbide mononitrate is used to for the the prophylactic treatment of angina pectoris; that is, it is taken in order to prevent or at least reduce the occurrence of angina. Research on Isosorbide mononitrate as a cervical ripener to reduce time at hospital to birth is supportive.</p>
<p>Isosorbide mononitrate is an active metabolite of isosorbide dinitrate and exerts qualitatively similar effects. Isosorbide mononitrate reduces the workload of the heart by producing venous and arterial dilation. By reducing the end diastolic pressure and volume, isosorbide mononitrate lowers intramural pressure, hence leading to an improvement in the subendocardial blood flow. The net effect when administering isosorbide mononitrate is therefore a reduced workload for the heart and an improvement in the oxygen supply/demand balance of the myocardium.</p>
<p>The adverse reactions which follow have been reported in studies with isosorbide mononitrate:<br>
Very common. Headache predominates (up to 30%) necessitating withdrawal of 2 to 3 % of patients, but the incidence reduces rapidly as treatment continues .<br>
Common. Tiredness, sleep disturbances (6%) and gastrointestinal disturbances (6%) have been reported during clinical trials with isosorbide mononitrate modified release tablets, but at a frequency no greater than for placebo. Hypotension (4 to 5%), poor appetite (2.5%), nausea (1%).<br>
Adverse effects associated with the clinical use of the drug are as expected with all nitrate preparations. They occur mainly in the early stages of treatment.<br>
Hypotension (4%) with symptoms such as dizziness and nausea (1%) have been reported. These symptoms generally disappear during long-term treatment.<br>
Other reactions that have been reported with isosorbide mononitrate modified release tablets include tachycardia, vomiting, diarrhoea, vertigo and heartburn</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01020/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01020/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01020.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01020.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01020.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01020.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01020.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01020">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Isosorbidi Mononitras</td><td>Latin</td><td>INN</td></tr><tr><td>Mononitrate d'Isosorbide</td><td>French</td><td>INN</td></tr><tr><td>Mononitrato de Isosorbida</td><td>Spanish</td><td>INN</td></tr><tr><td>Monosorbitrate</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Chemydur</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Corangin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Dilatrate</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Duride</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Elantan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Etimonis</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Imdur</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Imodur</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Imtrate</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ismexin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ismo</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ismox</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Isomon</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Isomonit</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Isonorm</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Medocor</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Monicor</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Monit</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Mono Corax</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Mono Mack</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Monocedocard</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Monoclair</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Monocord</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Monodur Durules</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Monoket</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Monolong</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Monomax</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Mononit</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Monopront</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Monosorb</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Monosordil</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Monotrate</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Nitramin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Olicard</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Olicardin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Orasorbil</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Pertil</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Plodin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Promocard</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Sigacora</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Solotrate</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Sorbimon</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Turimonit</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Uniket</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Vasdilat</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/vasodilator-agents">Vasodilator Agents</a></li>
<li><a href="/mesh/nitric-oxide-donors">Nitric Oxide Donors</a></li></ul></td></tr><tr><th>CAS number</th><td>16051-77-7</td></tr><tr><th>Weight</th><td>Average: 191.1388<br>Monoisotopic: 191.042987025</td></tr><tr><th>Chemical Formula</th><td>C<sub>6</sub>H<sub>9</sub>NO<sub>6</sub></td></tr><tr><th>InChI Key</th><td>YWXYYJSYQOXTPL-SLPGGIOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C6H9NO6/c8-3-1-11-6-4(13-7(9)10)2-12-5(3)6/h3-6,8H,1-2H2/t3-,4+,5+,6+/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(3R,3aS,6S,6aR)-6-hydroxy-hexahydrofuro[3,2-b]furan-3-yl nitrate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Furofurans</td></tr><tr><th>Subclass</th><td>Isosorbides</td></tr><tr><th>Direct parent</th><td>Isosorbides</td></tr><tr><th>Alternative parents</th><td>Tetrahydrofurans; Nitrate Esters; Organic Nitrates; Oxolanes; Nitro Compounds; Secondary Alcohols; Polyamines; Ethers</td></tr><tr><th>Substituents</th><td>tetrahydrofuran; nitrate ester; organic nitrate; oxolane; secondary alcohol; organic nitric acid or derivative; nitro compound; polyamine; ether; alcohol</td></tr><tr><th>Classification description</th><td>This compound belongs to the isosorbides. These are organic polycyclic compounds containing an isosorbide(1,4-Dianhydrosorbitol) moiety, which consists of two -oxolan-3-ol rings.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the prevention of angina pectoris due to coronary artery disease and the treatment of acute and chronic angina pectoris, hypertension, and myocardial infarction.</td></tr><tr><th>Pharmacodynamics</th><td>Isosorbide-5-mononitrate, the long-acting metabolite of isosorbide dinitrate, is used as a vasodilatory agent in the management of angina pectoris. By dilating the vessels, it lowers the blood pressure and reduces the left ventricular preload and afterload, therefore, leads to a reduction of myocardial oxygen requirement.</td></tr><tr><th>Mechanism of action</th><td>Similar to other nitrites and organic nitrates, Isosorbide Mononitrate is converted to nitric oxide (NO), an active intermediate compound which activates the enzyme guanylate cyclase (Atrial natriuretic peptide receptor A). This stimulates the synthesis of cyclic guanosine 3',5'-monophosphate (cGMP) which then activates a series of protein kinase-dependent phosphorylations in the smooth muscle cells, eventually resulting in the dephosphorylation of the myosin light chain of the smooth muscle fiber. The subsequent release of calcium ions results in the relaxation of the smooth muscle cells and vasodilation.</td></tr><tr><th>Absorption</th><td>100%</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>0.6 to 0.7 L/kg</li>
</ul></td></tr><tr><th>Protein binding</th><td>5%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic</p></td></tr><tr><th>Route of elimination</th><td>Isosorbide mononitrate is primarily metabolized by the liver, but unlike oral isosorbide dinitrate, it is not subject to first-pass metabolism.
Isosorbide mononitrate is cleared by denitration to isosorbide and glucuronidation as the mononitrate, with 96% of the administered dose excreted in the urine within 5 days and only about 1% eliminated in the feces. At least six different compounds have been detected in urine, with about 2% of the dose excreted as the unchanged drug and at least five metabolites.</td></tr><tr><th>Half life</th><td>5 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>120&#8211;122 mL/min [Single dose of 60 mg PO]</li>
	<li>151&#8211;187 mL/min [Single dose of extended-release tablet 60 mg PO]</li>
	<li>132-151 mL/min [Multiple doses of extended release tablet 60 mg PO]</li>
	<li>119-140 mL/min [Multiple doses of extended release tablet 120 mg PO]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Symptoms of overdose include vasodilatation, venous pooling, reduced cardiac output, and hypotension. There are no data suggesting what dose of isosorbide mononitrate is likely to be life-threatening in humans. In rats and mice, there is significant lethality at doses of 2000 mg/kg and 3000 mg/kg, respectively.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9156</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9355</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.579</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7621</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7159</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8563</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8674</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8613</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5357</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8532</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8769</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9106</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8469</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9471</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9596</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9133
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7696
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Ready biodegradable 
        </td>
        <td>
            0.8359
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.0753 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.5741
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9304
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Schering plough corp</li>
<li>Actavis elizabeth llc</li>
<li>Brightstone pharma inc</li>
<li>Dexcel ltd</li>
<li>Elan pharmaceutical research corp</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Kremers urban co</li>
<li>Kv pharmaceutical co</li>
<li>Vintage pharmaceuticals inc</li>
<li>West ward pharmaceutical corp</li>
<li>Promius pharma llc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Schwarz gmbh</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.actavis.com">Actavis Group</a></li>
<li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.alvogen.com">Alvogen Inc.</a></li>
<li><a href="http://www.apothecon.nl">Apothecon</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.astrazeneca.ca">AstraZeneca Inc.</a></li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li><a href="http://www.dexcel.com">Dexcel Ltd.</a></li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.elan.com">Elan Pharmaceuticals Inc.</a></li>
<li><a href="http://www.ethex.com">Ethex Corp.</a></li>
<li>Heartland Repack Services LLC</li>
<li>Ivax Pharmaceuticals</li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li>Neuman Distributors Inc.</li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.promiuspharma.com">Promius Pharma</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.schering.de">Schering Corp.</a></li>
<li>Schwarz Pharma Inc.</li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li>Vangard Labs Inc.</li>
<li><a href="http://www.west-ward.com">West-Ward Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr><tr><td>Tablet, extended release</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB06237">Avanafil</a></td><td>Additive vasodilation. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00320">Dihydroergotamine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01253">Ergonovine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00696">Ergotamine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00353">Methylergometrine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00247">Methysergide</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00203">Sildenafil</a></td><td>Possible significant hypotension with this combination</td></tr><tr><td><a href="/drugs/DB00820">Tadalafil</a></td><td>The vasodilatory effects of Isosobide mononitrate may be increased by Tadalafil. Severe hypotension may occur. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Isosorbide Mononitrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Isosorbide Mononitrate if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr><tr><td><a href="/drugs/DB06267">Udenafil</a></td><td>The vasodilatory effects of Isosobide mononitrate may be increased by Udenafil. Severe hypotension may occur. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00862">Vardenafil</a></td><td>The vasodilatory effects of Isosorbide mononitrate may be increased by Vardenafil. Severe hypotension may occur. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of isosorbide mononitrate by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of isosorbide mononitrate if voriconazole is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals.</li></ul></td></tr></tbody></table>